Schmouder R - Search Results

1

Pharmacokinetics, pharmacodynamics, safety, and tolerability of single-dose fingolimod (FTY720) in adolescents with stable renal transplants.

Ettenger R, Schmouder R, Kovarik JM, Bastien MC, Hoyer PF. Ettenger R, et al. Among authors: schmouder r. Pediatr Transplant. 2011 Jun;15(4):406-13. doi: 10.1111/j.1399-3046.2011.01498.x. Pediatr Transplant. 2011. PMID: 21585629 Clinical Trial.

2

Pharmacokinetics of enteric-coated mycophenolate sodium in stable pediatric renal transplant recipients.

Ettenger R, Bartosh S, Choi L, Zhu W, Niederberger W, Campestrini J, Bastien MC, Schmouder R. Ettenger R, et al. Among authors: schmouder r. Pediatr Transplant. 2005 Dec;9(6):780-7. doi: 10.1111/j.1399-3046.2005.00386.x. Pediatr Transplant. 2005. PMID: 16269051 Clinical Trial.

3

Clinical pharmacokinetics of fingolimod.

David OJ, Kovarik JM, Schmouder RL. David OJ, et al. Clin Pharmacokinet. 2012 Jan 1;51(1):15-28. doi: 10.2165/11596550-000000000-00000. Clin Pharmacokinet. 2012. PMID: 22149256 Review.

4

FTY720 pharmacokinetics in mild to moderate hepatic impairment.

Kovarik JM, Schmouder RL, Serra D, Wang Y, Wiegand H, Dilzer SC, Lasseter KC. Kovarik JM, et al. Among authors: schmouder rl. J Clin Pharmacol. 2005 Apr;45(4):446-52. doi: 10.1177/0091270004274288. J Clin Pharmacol. 2005. PMID: 15778425

5

Single-dose FTY720 pharmacokinetics, food effect, and pharmacological responses in healthy subjects.

Kovarik JM, Schmouder R, Barilla D, Wang Y, Kraus G. Kovarik JM, et al. Among authors: schmouder r. Br J Clin Pharmacol. 2004 May;57(5):586-91. doi: 10.1111/j.1365-2125.2003.02065.x. Br J Clin Pharmacol. 2004. PMID: 15089811 Free PMC article. Clinical Trial.

6

Multiple-dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects.

Kovarik JM, Schmouder R, Barilla D, Riviere GJ, Wang Y, Hunt T. Kovarik JM, et al. Among authors: schmouder r. J Clin Pharmacol. 2004 May;44(5):532-7. doi: 10.1177/0091270004264165. J Clin Pharmacol. 2004. PMID: 15102874 Clinical Trial.

7

FTY720: placebo-controlled study of the effect on cardiac rate and rhythm in healthy subjects.

Schmouder R, Serra D, Wang Y, Kovarik JM, DiMarco J, Hunt TL, Bastien MC. Schmouder R, et al. J Clin Pharmacol. 2006 Aug;46(8):895-904. doi: 10.1177/0091270006289853. J Clin Pharmacol. 2006. PMID: 16855074 Clinical Trial.

8

Overview of FTY720 clinical pharmacokinetics and pharmacology.

Kovarik JM, Schmouder RL, Slade AJ. Kovarik JM, et al. Ther Drug Monit. 2004 Dec;26(6):585-7. doi: 10.1097/00007691-200412000-00001. Ther Drug Monit. 2004. PMID: 15570180 Review.

9

Fingolimod (FTY720) in severe hepatic impairment: pharmacokinetics and relationship to markers of liver function.

Kovarik JM, Schmouder RL, Hartmann S, Riviere GJ, Picard F, Voss B, Weiss M, Wagner F, Schmidt HH. Kovarik JM, et al. J Clin Pharmacol. 2006 Feb;46(2):149-56. doi: 10.1177/0091270005283464. J Clin Pharmacol. 2006. PMID: 16432266 Clinical Trial.

10

Oral-intravenous crossover study of fingolimod pharmacokinetics, lymphocyte responses and cardiac effects.

Kovarik JM, Hartmann S, Bartlett M, Riviere GJ, Neddermann D, Wang Y, Port A, Schmouder RL. Kovarik JM, et al. Biopharm Drug Dispos. 2007 Mar;28(2):97-104. doi: 10.1002/bdd.535. Biopharm Drug Dispos. 2007. PMID: 17230596 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

67 results

Search Page